KRASG12C IN-18

KRASG12C IN-18 is an orally active covalent KRASG12C inhibitor that achieves complete covalent engagement of KRASG12C in both GDP- and GMPPNP-bound states and displays strong antiproliferative activity against KRASG12C and resistance-associated variants, including KRASG12C/R68S, with low-nanomolar IC50 values. KRASG12C IN-18 exhibits marked in vivo efficacy in KRASG12C-driven solid tumor and KRASG12C/R68S xenograft models and can be used for colorectal cancer research[1].

Product Specifications

CAS Number

[2966924-24-1]

UNSPSC

12352005

Target

Ras

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Field of Research

Cancer

Smiles

N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C=C(F)C(C4=C5C(C#C)=C(F)C=CC5=CC=C4)=C(F)C3=NC(OCC67CCCN6CCC7)=N2)C1

Molecular Formula

C37H32F4N6O2

Molecular Weight

668.68

References & Citations

[1]Gao K, et al. Structure-based design and synthesis of novel highly potent and selective KRASG12C inhibitors. Eur J Med Chem. 2026;302 (Pt 2) :118321. doi:10.1016/j.ejmech.2025.118321